RESEARCH DOSSIER
Insurance Product Governance Committee Decision Protocols
Abstract. Insurance product governance committees convert contractual design, actuarial estimates, legal requirements, commercial incentives and customer evidence into accountable decisions about placing products on the market and maintaining them over time. This monograph investigates the institutional organization of that decision process, the sufficiency of evidence at approval and review, independent challenge, conflicts of interest, target-market and distribution controls, and the restoration of accountable oversight after adverse outcomes. It compares selected international supervisory standards, European Union product oversight and governance requirements, United Kingdom fair-value rules, and the United States annuity best-interest model. Organizational decision research provides a bounded explanation of why collective approval can fail despite individual technical competence. The study distinguishes mandatory obligations from operational arrangements that institutions may adopt to implement them. It develops a source-critical synthesis of decision rights, evidence quality and lifecycle accountability, supported by regulatory observations and explicit worked examples. The central conclusion is that approval is credible when the authorized decision-maker can demonstrate the compatibility of a defined product, customer population and distribution arrangement, manage material disagreement, and retain the practical ability to intervene when the assumptions supporting approval cease to hold. The work is a comparative institutional analysis, not an estimate of committee effectiveness or a new theoretical system.
Keywords: Insurance product governance; product oversight and governance; approval committee; decision rights; independent challenge; target market; product testing; fair value; conduct risk; distribution governance; conflicts of interest; escalation; customer outcomes; regulatory supervision.
Introduction
Research object and analytical method
An insurance product approval decision authorizes a specified arrangement for transferring risk. Its economic significance extends beyond the contractual wording: premium structure, eligibility, exclusions, limits, renewal terms, distribution incentives, service capacity and claims practices together determine the protection that a customer can actually obtain. A product committee is an institutional arrangement through which these dimensions are examined together. Its distinctive object is the decision itself: who may authorize it, what evidence makes authorization defensible, who can challenge it, how dissent is resolved and how authorization remains connected to later outcomes.
The underlying problem arises because information is distributed across functions. Pricing staff understand assumptions about incidence and severity; claims staff observe operational obstacles; legal specialists interpret coverage and obligations; distributors observe purchase behavior; customer research may reveal comprehension difficulties. Commercial sponsors may possess the clearest account of the intended market and the largest incentive to launch quickly. A committee must assemble these partial perspectives without allowing the most visible or profitable story to substitute for the total decision record.
The method is comparative institutional and legal analysis, decision-right mapping, bounded interpretation of organizational research, and transparent hypothetical calculations. The study examines selected instruments and observations as available on November 19, 2026. It uses current rulebook text where retrieved, distinguishes supervisory standards from binding jurisdictional obligations, and marks illustrative recommendations as analytical judgments. It does not inspect confidential insurer committee minutes, estimate causal effects, rank jurisdictions, or establish the incidence of misconduct. The United States analysis is deliberately confined to the annuity model and its implications; state enactments and all product-specific filing requirements are outside scope. The European Union analysis focuses on decision-process provisions, rather than attempting a complete account of every subsequent amendment and national implementing measure.
The comparative regulatory foundation
The EU Insurance Distribution Directive's Article 25, adopted in 2016, connects approval, an identified customer population, risk assessment, distribution and continuing review. The associated 2017 delegated regulation's product approval process assigns ultimate responsibility to the manufacturer's responsible body or structure. The regulatory object is an effective documented process, proportionate to product and business risk. The texts examined do not prescribe a universal committee title, numerical quorum or voting formula.
The international ICP 19 (IAIS, 2024, section 19.5) recognizes both supervisory approval and principles-based approaches, including combinations. The former concerns a supervisor's premarket examination; the latter allocates responsibility for appropriate product development to the institution. A manufacturer's committee approval and a supervisor's authorization are therefore separate events; neither should be inferred from the existence of the other. The committee needs a jurisdiction-specific map of relevant filing, licensing and conduct obligations before activation.
Product Committee Institutional Design
Authority and accountability
The institutional charter should identify the appointing body, delegated powers, product classes and legal entities covered, escalation thresholds, meeting and voting arrangements, and the relationship between product approval and other corporate decisions. A product may require several distinct authorizations: wording acceptance, price and capital signoff, operational readiness, distribution authorization and formal launch. Assigning these decisions prevents a committee from treating a narrow technical approval as authority to open every distribution channel.
The manufacturer's governing structure remains accountable for the process under the EU delegated regulation's Article 4 (European Commission, 2017). Delegating preparatory work or meeting administration is compatible with retaining responsibility. A group committee that serves multiple underwriting entities must identify the entity whose policyholders bear the consequences. Local management should have a clear route for escalating constraints that do not apply elsewhere in the group.
The organizational rationale has a broader intellectual foundation. Fama and Jensen (1983) associate specialization with the need to control agency problems. Applied to product governance, the implication is that a person who originates a proposal should not be its only effective evaluator. The cited abstract supports the general organizational argument; the application to insurance committee arrangements is the author's institutional interpretation, not a reported test of these committees.
Decision rights and functional participation
The following allocation is an illustrative design, adjustable to authority, risk, size and local law. It distinguishes responsibilities for producing evidence from rights to challenge and authorize action.
| Function | Evidence responsibility | Decision contribution |
|---|---|---|
| Product sponsor | Customer need, design, business forecasts | Proposes and owns implementation |
| Actuarial and underwriting | Assumptions, pricing, risk selection, uncertainty | Challenges adequacy and risk exposure |
| Legal and compliance | Applicable rules, contract and disclosure alignment | Identifies legal constraints and escalation |
| Risk and capital | Risk appetite, concentration, capital and stress | Challenges aggregate and residual exposure |
| Claims and operations | Claim journeys, service and system capacity | Tests deliverability |
| Distribution and customer insight | Channel suitability, remuneration, actual customer evidence | Tests target-market access and outcomes |
| Authorized chair and members | Synthesis and documented disposition | Decide within delegated authority |
| Internal audit | Retrospective assurance on control effectiveness | Independently assesses process; generally avoids routine business approval |
A small insurer may combine roles, use appropriately qualified external specialists or refer significant conflicts to an independent body. The test is whether combined roles obscure competing responsibilities or compromise meaningful challenge. An auditor who routinely approves a product may later be asked to assure its own judgment. Participation, consultation, voting membership and assurance are separate assignments.
A charter can reserve decisions of exceptional significance to a higher body: a new jurisdiction, a material increase in uncertainty, dependence on an untested platform, a conflict with risk appetite, or changes that may harm an existing customer cohort. Reservation is especially useful when the committee is tempted to treat a strategic commercial decision as an ordinary delegated adjustment. A delegated limit should be expressed through recognizable conditions instead of permitting case-by-case reinvention by the sponsor.
Quorum, voting and emergency authority
Quorum specifies whether a meeting is competent to decide; the voting rule specifies how a competent meeting reaches a disposition. An illustrative committee might require a majority of eligible members and attendance by designated risk and compliance roles, with a separate escalation instruction if a required member is conflicted. Counting attendees instead of eligible decision-makers makes recusal ineffective.
Consider seven voting positions, five eligible members present, and four affirmative votes. A rule requiring a majority of eligible votes cast can authorize a decision, whereas a rule requiring five affirmative votes cannot. The charter must specify the denominator, treatment of abstentions and recusals, and whether written resolutions require equivalent participation. A casting vote cannot cure lack of jurisdiction or mandatory supporting evidence. Unanimity can create pressure to conceal disagreement; simple majority can permit systematic exclusion of a minority function. Different voting rules allocate these risks differently.
Emergency authority is most useful for protective action, such as restricting an affected sales channel when delayed intervention may expose additional customers. Subsequent review should examine the trigger, temporary scope, treatment of existing contracts and evidence for lifting the restriction. Urgency should not be used as a substitute for the ordinary approval process when a firm is simply seeking to meet its launch target.
Approval Gates and Evidentiary Requirements
A decision package and its evidentiary purpose
A proposal identifies the exact product variant, insurer, geography, contractual version, premium basis, intended clientele, distribution methods, proposed dates and lifecycle owner. Evidence should then answer distinct questions: why the product is needed, how it transfers risk, whether price and contractual performance remain sustainable, whether the target population can use it, whether channels deliver it as intended, and whether the insurer can administer and monitor it. An executive summary should identify unresolved uncertainties and opposing evidence instead of compressing them out of sight.
Under the delegated regulation's Article 6 product testing (European Commission, 2017), manufacturers test appropriate scenarios where relevant, use qualitative and risk-dependent quantitative tests, and must refrain from launch if results demonstrate a mismatch with target-market needs. Testing concerns lifetime compatibility, not simply acceptance of the launch forecast. The committee should distinguish a completed test with unfavorable results from an incomplete test whose results remain unknown. Both may prevent launch, but their remediation is different.
Evidence quality has several dimensions: source provenance; relevance to the specified population and version; completeness and consistency; transparent assumptions; reproducibility; independence from sponsor incentives; and recency relative to the proposed effective date. A historical loss table may be accurate but unsuitable for a changed eligibility definition. A survey can be well-designed yet unrepresentative of customers using a different distribution channel. A supplier's certificate may answer a technical question but omit actual operational recovery capability.
For a novel product with sparse experience, reasonable extrapolation requires explaining the analog, known differences and limits. A credible package can use bounds, expert judgments and sensitivity analysis when direct observations do not exist. The committee should identify which uncertainty can be monitored after launch and which prevents safe authorization now. A proposed pilot remains subject to applicable approval obligations and consumer protections; describing it as a pilot does not excuse an unmet prerequisite.
Actuarial adequacy and consumer value
A technical premium analysis asks whether expected claim costs, expense requirements, uncertainty and financing can be supported. A schematic annual net claim estimate for a homogeneous exposure population is frequency multiplied by mean covered severity. A real product may require segmentation, dependency analysis, inflation, trend, contract boundaries, expenses, reinsurance and capital assessment. Actuarial adequacy and customer value are related but distinct propositions.
Under FCA PROD 4.2 (FCA, 2026, rules 4.2.14A-E), applicable non-investment products require a demonstrable relationship between price and product or service quality, including relevant packages and foreseeable renewal. A failure to identify and demonstrate fair value prevents marketing unless appropriate changes ensure value. The committee therefore needs both the economics of providing protection and the economics of obtaining it. The total price paid by customers, remuneration, barriers to using benefits and quality of service can matter even when the insurer's net premium is technically defensible.
An illustrative annual policy has premium 120 monetary units, expected covered claims 36, distribution cost 36, administration 24, and residual 24 before capital charges, tax and other omitted costs. The expected covered-claim share is 30%; distribution cost is another 30%. If a redesign reduces distribution cost by 12 and reduces price by 12 while keeping the other assumptions fixed, the premium becomes 108 and the residual remains 24. The expected claims share becomes 36/108, or 33.3%. This calculation establishes a possible price and remuneration tradeoff under fixed assumptions; it proves neither fair value nor profitability. Actual behavior, coverage quality, cost changes and selection responses may differ after redesign.
A committee reviewing alternatives should ask whether a higher commission buys a valuable service, whether that service is used, and whether the customer could obtain comparable protection more efficiently through another arrangement. It should also test whether lowering price can induce significant changes in risk mix and whether widening coverage improves meaningful protection while increasing claim costs. Fair value is a substantive relationship, not a universal minimum payout percentage.
Evidence thresholds and conditional decisions
A useful distinction separates prerequisites from judgments within tolerance. An unmet binding legal requirement, failed mandatory test or inability to demonstrate a required value assessment cannot be offset by forecast profit. A completed and favorable test with a manageable residual uncertainty may justify a limited decision if constraints, owner, timeframe and monitoring are explicit. A committee should avoid weighted scoring that permits excellent sales prospects to cancel a fundamental failure of customer protection.
The available dispositions can include approval, approval with enforceable conditions, deferral for further evidence, rejection, restriction or withdrawal. Conditions should be classified as pre-activation or post-activation. A pre-activation condition suspends the permission to sell until an authorized person verifies closure. Post-activation conditions concern permissible residual monitoring, not known unmet prerequisites. A decision to defer should state what evidence is missing and why it matters; indefinitely requesting better documentation without identifying the underlying question is poor use of governance capacity.
Internal Challenge and Conflicts Management
Why consensus can be misleading
Collective decisions depend on what information enters discussion. The abstract of the meta-analysis by Lu, Yuan, and McLeod (2012) reports a tendency for groups to discuss common information more than uniquely held information, and an association between unique-information coverage and decision quality. These findings concern experimental group decision settings, not an insurance-specific field sample. They nevertheless provide a reason to design meetings that actively elicit evidence held by individual functions.
A common briefing can make forecasts familiar to every member while the single claims practitioner who knows that a documentation requirement is hard to satisfy hesitates to speak. The information advantage of a multidisciplinary committee disappears if each member learns only the sponsor's framing. Circulating independent opinions before the meeting, requiring an explicit account of contrary evidence and requesting unshared operational observations can help reveal otherwise neglected information.
Independent challenge needs time and access to the underlying files. A last-minute presentation does not create an effective opportunity to examine model assumptions or review policy language. The chair should ensure that late material revisions either receive examination or result in deferral. In an abbreviated low-risk procedure, the required functions can provide written assessments rather than meet synchronously; the record still needs to support the decision.
Dissent, objections and escalation
Different objections imply different consequences. An actuarial reviewer may question an assumption without rejecting the product. A legal reviewer may identify a non-permissible term requiring amendment. A conduct reviewer may observe that the evidence for a customer benefit is missing. Treating these objections as interchangeable encourages an artificial consensus rather than resolving the decision issue.
A challenge record should identify the contested proposition, its evidence, significance, response, residual uncertainty, disposition and any appeal route. The proposer may rebut the objection with better evidence; the authorized decision-maker can accept justified residual risk within authority. A legal prohibition or delegated-limit breach should be escalated or corrected rather than outvoted. A persistent unresolved technical disagreement might justify independent expert review without implying that every minority opinion has a veto.
Consider a product with a proposed 30-day document submission limit. Claims identifies a group of customers who frequently obtain a required third-party document only after 45 days. The legal team may find the proposed wording permissible in the relevant jurisdiction, while customer insight questions its practical utility. An appropriate committee response is to examine the incidence, causal mechanism, alternative documentation and pricing consequences. The decision is about contract performance and customer harm, not simply the legal acceptability of a sentence.
Incentives and conflicts
Commercial rewards can bias the timing and framing of evidence. A committee should distinguish institutional incentives shared by many members from personal interests requiring disclosure or recusal. A manufacturer's dependence on a distribution partner may also create a significant economic conflict even when no committee member has a personal relationship with that partner. Article 4 expressly connects the approval process to conflicts management (European Commission, 2017).
Illustrative controls include disclosure at each decision, documented management of conflicts, recusal when appropriate, access to independent analysis, separate review of remuneration and an escalation pathway when the ordinary quorum cannot be maintained. The treatment of conflicts should be tied to the decision and not reduced to an annual declaration that provides no information about the proposal in question.
The NAIC's account of its annuity best-interest standard explains the February 2020 model revisions and strengthened supervision of recommendations. This is a US model instrument, whose legal application depends on enactment and circumstances; it is not an EU-style universal insurance product committee requirement. Its decision-process significance is that commission arrangements and producer supervision need to be considered before a product is distributed, especially where incentives could distort recommendations. An institutional decision cannot establish that every future individual recommendation will be appropriate.
Target-Market and Distributor Feedback Integration
Target market as an operating constraint
Target-market analysis specifies why a product is compatible with customers sharing defined needs, characteristics and objectives. The delegated regulation's Article 5 (European Commission, 2017) connects granularity to product complexity and risk and considers customers' ability to understand the product. A committee should ask how each characteristic matters for the product rather than creating unnecessarily restrictive segments.
For travel insurance, trip duration, geography, preexisting-condition treatment, activities, emergency assistance and eligibility can determine compatibility. For a long-duration savings-related contract, costs, liquidity, investment risk, time horizon and exit terms become part of the assessment. An excessively broad statement such as all adults in the domestic market provides little useful direction. An overly narrow specification may restrict otherwise compatible customers without justification. A target market describes general compatibility; applicable individual demands-and-needs, advice or suitability obligations must be handled separately.
The approval record should state the positive target population, any identified incompatible groups where relevant, how the distributor can recognize them, and which assumptions will be monitored. A product test should examine not only whether a claimant could theoretically qualify for a benefit, but whether the intended population could reasonably navigate the claim process. Segment differences should have a documented relationship to insurance need, lawful underwriting or effective delivery.
Distribution design and handoff
The EU directive's Article 25 requires transmission of appropriate product and approval information to distributors. The practical implication is that the committee authorizes a defined combination of product and channel, rather than an abstract contract. A clear handoff identifies the policy version, approved customer groups, necessary disclosures, restrictions on sales, appropriate training, remuneration, reporting requirements and changes requiring prior notification.
The manufacturer should require a distributor to establish how it uses that information in practice. An acknowledgment of receipt shows delivery, not operational comprehension. Sampling sales journeys, checking scripts, observing exceptions and testing data exchanges can help evaluate implementation. For embedded insurance, the surrounding checkout sequence and noninsurance purchase may shape whether customers appreciate that the policy is optional or understand its scope.
Distribution feedback closes a structural information gap. The carrier often has the claim result while the distributor knows what was represented at purchase. A review should reconcile customer identifiers consistently with applicable privacy requirements, preserve relevant product and channel dimensions, and investigate repeated exceptions. Outsourced functions and intermediaries do not remove the carrier's continuing concern with conduct, consistent with the IAIS description of lifecycle responsibility in ICP 19.0.8-10.
Monitoring measures and interpretation
Let N denote the number of reported claims in a defined period, A the number accepted under a consistently specified outcome definition, and P the number pending at the observation date. A committee should avoid silently treating pending claims as rejected. If 100 claims are reported, 72 accepted, 8 rejected and 20 pending, the acceptance share among resolved cases is 72/(72+8) = 90%, while 72/100 = 72% is the proportion of all reported cases accepted by cutoff. Both are valid for their explicitly stated denominators but answer different questions. If pending cases differ systematically by complexity, neither is an unbiased prediction of ultimate acceptance.
Monitoring should distinguish exposure-based measures from claim-based measures and preserve cohort and reporting dates. The FCA's 2025 value measures publication (2026) cautions that product mix, age, policy length, target market, volume and reporting issues influence interpretation. A committee should avoid mechanically transferring a market benchmark into a launch threshold for a different portfolio.
Suppose 12 of 300 customers acquired through one channel make a complaint and 6 of 600 from another. The descriptive proportions are 4% and 1%. The difference is 3 percentage points. Before attributing the difference to distribution conduct, examine product mix, tenure, contact accessibility, complaint-recording practices, sampling error and service arrangements. A higher complaint rate may indicate worse outcomes or better complaint accessibility. The observation is an investigation trigger, not evidence by itself of intentional mis-selling.
Documentation, Review and Escalation
The decision record
A decision record establishes what was authorized, by whom, on what evidence and under what constraints. It needs more than minutes stating that all members agreed. Reconstructability requires a document identifier and exact approved version; meeting date, attendance, quorum and declared conflicts; evidence pack identifiers; key disputed propositions; resolution and votes; conditions with owners and dates; activation instructions; and review triggers.
The record should distinguish the evidence available before the decision from information generated afterward. Later findings may justify revision and should be linked through a dated subsequent decision; retrospective editing of the original rationale erodes the ability to understand why the initial choice was made. Version control matters particularly when small wording or price changes affect a product that remains marketed under the same name.
Documentation should be proportionate to risk. For routine corrections, a concise written delegation record may be enough; for novel, complex or high-impact products, detailed scenario results and competing opinions may be essential. In both cases, retain evidence under applicable rules and institutional policy, including protection for customer and employee information. An auditable record must remain available to authorized readers without indiscriminate distribution of sensitive data.
Monitoring, thresholds and intervention
Under Article 7 product monitoring (European Commission, 2017), manufacturers continuously monitor and regularly review marketed products, set appropriate review intervals, and mitigate identified adverse circumstances with prompt communication to affected parties. A scheduled review is not a reason to postpone action on a material event.
The committee needs predetermined triggers with room for contextual judgment. A product review could be triggered by a material change in legal requirements, altered distribution incentives, a growing concentration of claim denials, unexpected cancellations, customer complaints, system failures, pricing or inflation changes, or emerging mismatch between customer needs and actual coverage. Each trigger should have its data definition, frequency, responsible owner and escalation recipient. A missing data feed is itself a reason to investigate the reliability of oversight.
Thresholds are not diagnoses. A high denial rate may result from proper application of a clear exclusion, yet repeated misunderstanding may indicate a design or distribution problem. Conversely, a low complaint count may conceal poor awareness of reporting channels. Combining quantitative monitoring with case reviews and customer evidence helps interpret signals without claiming more precision than the data support.
An intervention must specify whether it affects further sales, renewal, policy wording, distributor access, claims treatment or existing customers. Withdrawal of new business does not extinguish obligations under existing contracts. A committee should map affected cohorts, legal constraints, communication plans and possible remediation before closing the issue. The appropriate authorized decision-maker must also assess regulatory notification duties where applicable.
Reapproval and closure
A post-sale review can confirm authorization, require changes, restrict sales, defer a decision for necessary evidence or recommend withdrawal. Reapproval of a redesigned product should address the facts that undermined the original decision. Merely reporting that the sponsor has delivered an action item does not demonstrate that the customer problem has been corrected.
Closure evidence should match the intervention: corrected contract and system versions for wording changes, tested scripts and observed practice for distributor training, validated counts for remediation, and subsequent outcome review where appropriate. A committee can distinguish implementation closure from effectiveness review when changes need time to affect outcomes. If no customer has yet made a claim, it may be too early to establish the long-term effect of a new process. Record that limitation without losing ownership of the future review.
Comparative Decision Failures and Design Safeguards
Evidence from supervisory practice
The FCA's 2024 thematic review findings examined information from 28 manufacturers and 39 distributors covering ten products. Its official summary identifies shortcomings in manufacturers' evidence of value and distributors' understanding of remuneration and its effect on value. This is direct evidence of shortcomings found in the reviewed arrangements. It does not report randomized allocation to governance designs or establish that any particular voting rule caused the weaknesses.
A separate European perspective appears in EIOPA's 2026 peer review follow-up summary, which describes advances in nationally implemented supervision after the 2023 peer review, including movement toward operational and risk-focused approaches. This is evidence about supervisory frameworks, not a longitudinal measurement of insurer committee effectiveness. It illustrates why a supervisory authority may seek evidence of outcomes and actual operational processes in addition to an approved policy.
The two observations converge at the level of institutional interpretation: a written approval policy can describe how decisions should occur, while actual value assessment, data flows and corrective action establish whether the process operates. The significance of the convergence does not depend on treating the two supervisory exercises as comparable samples or equivalent regulatory regimes.
GAP insurance and the logic of suspended authorization
On February 9, 2024, the FCA's GAP sales suspension announcement reported that firms accounting for 80% of that market agreed to pause sales after regulatory intervention over value concerns. The announcement describes a protective response, not a finding about every policy or every firm. GAP coverage can address a real financial shortfall after a vehicle is written off; the question was whether actual arrangements delivered appropriate value.
The regulator's May 2024 restart announcement reported that renewed distribution depended on demonstrating fair value, with lower commissions among restarting firms. It stated that 2022 market measures showed claim payouts equivalent to 6% of premiums, with some commissions reaching 70%. The percentages have different scopes: the claims figure is a market observation, while the commission figure concerns some firms. They cannot be combined into a representative insurer income statement.
The study draws three bounded implications. First, a committee must be able to distinguish product usefulness from the value of a particular pricing and distribution arrangement. Second, the appropriate response to deficient evidence can be a sales restriction that preserves existing contractual obligations while the arrangement is reviewed. Third, reactivation should depend on evidence of the revised product and its implementation, not simply the passage of time. No public source reviewed here discloses the relevant firms' committee minutes or voting records; internal failures and individual responsibilities cannot be reconstructed from the announcements.
Failure mechanisms and safeguards
| Observed or hypothesized mechanism | Decision safeguard | Limit of safeguard |
|---|---|---|
| Sponsor dominates shared information | Independent technical opinions and deliberate elicitation of contrary facts | Does not guarantee accurate evidence |
| Customer population described too broadly | Explicit compatibility and channel tests | Requires lawful and relevant segmentation |
| Financial viability substitutes for value | Separate evidence for price, quality and economics | Quantitative proxies cannot capture every benefit |
| Conditions remain open at launch | Verified pre-activation closure and system control | Needs current version and reliable controls |
| Monitoring loses channel visibility | Reconciled cohort and distributor data | Privacy and data quality constrain inference |
| Protective action lapses without proof | Time-bound restriction with evidence-based reapproval | Requires authority and actual enforcement |
These are analytical safeguards rather than empirically ranked interventions. Their usefulness depends on the failure mechanism: increasing meeting frequency will not repair a missing data feed; collecting more customer research will not by itself change a conflicted vote. A committee may use its time more effectively by identifying the decision's bottleneck before selecting a control.
A complete hypothetical decision
Suppose an insurer proposes a retail device-protection policy distributed through a retailer. The sponsor forecasts 10,000 policies at an annual price of 100, producing 1,000,000 gross written premium in a simplified one-year illustration. Expected covered claims are 250,000, distribution remuneration 350,000, administration 200,000, and the arithmetic residual is 200,000 before other charges. A small qualitative test indicates that some customers expect accidental damage cover even though the draft excludes several common accidents. The retailer's electronic journey presents the benefit description prominently but buries the exclusions.
The committee should separate the favorable business projection from the unresolved evidence on customer compatibility. Legal can assess the precise wording and sale disclosures; actuarial can calculate the cost of broadening coverage; claims can examine whether exclusions are practicable; distribution can redesign the journey. If appropriate tests establish a mismatch, a launch subject merely to later monitoring is inconsistent with the EU Article 6 approach where applicable. Under a relevant UK fair-value obligation, inability to demonstrate value similarly prevents marketing until appropriate modification.
The sponsor returns with a proposal to broaden coverage and reduce commission. Assume annual covered claims rise by 100,000 and distribution cost falls by 100,000, all other amounts unchanged. The arithmetic residual is unchanged. The revised scenario does not establish actual loss experience, customer understanding or service performance; revised testing and an authorized decision are required. A valid reapproval would bind the tested wording and distributor interface versions and specify what permissions can be activated. Post-sale monitoring would test whether the assumptions were reasonable and whether claims and sales data indicate a remaining mismatch.
This example illustrates the logic of decision revision without attributing the facts to a real firm. It also shows why product governance can improve both the customer proposition and the quality of commercial decisions: alternatives that initially appear incompatible with a margin target may have economically feasible configurations when all components are jointly examined.
Research limitations and future empirical work
The available material supports a comparative analysis of decision obligations, public supervisory observations and mechanisms of organizational information sharing. It does not establish a causal relationship between any committee design and policyholder outcomes. The organizational studies were assessed at abstract level, so their findings are not extended to unexamined subgroups, experimental protocols or effect moderators. The official IAIS text was available in extracted form; visual screenshot requests failed. The EU article-level rulebook texts support the specific provisions discussed; complete consolidated amendment histories and state-specific US legal comparisons were not undertaken.
A future empirical study could collect anonymized decision histories, product and channel identifiers, versions, dissent records, restrictions and subsequent outcomes. It would need to address selection into intensive oversight: higher-risk products may receive greater scrutiny and still have worse observed outcomes. Before-after comparisons would need to account for changes in risk, price, distribution, customer composition and reporting. Such research may test the relative effect of decision arrangements, but the present study makes no such claim.
Conclusion
Insurance product committee governance is a continuing allocation of decision rights and accountability across the life of a product. The comparative regulatory material establishes the significance of approval, customer compatibility, evidence, monitoring and intervention under different legal arrangements. The organizational analysis explains why assembling multiple functions can add value only when their information and objections enter the actual decision. The quantitative examples show why business viability, customer value and the measurement of outcomes require coherent definitions and explicit assumptions.
The principal analytical contribution is a synthesis of three connections: the connection between authority and evidence, the connection between independent challenge and substantive customer outcomes, and the connection between authorization and future intervention. The committee should have an identifiable mandate, clear limits and a record of how evidence was evaluated. A favorable decision should describe the product and distribution arrangement that may operate, including applicable prerequisites. Monitoring should retain the ability to identify when that decision needs reconsideration.
An approval is therefore a reasoned, traceable and revisable authorization within a defined institutional and legal setting. Its credibility depends on the continuing capacity to act when the conditions that supported it are no longer fulfilled. This conclusion is an interpretation of established regulatory requirements and decision research; no new doctrine, universal voting rule or causal estimate is asserted.
References
European Parliament and Council. (2016). Directive (EU) 2016/97 on insurance distribution, Article 25, Product oversight and governance requirements. Official Journal L 26, 2 February 2016; EIOPA rulebook. Source
European Commission. (2017). Commission Delegated Regulation (EU) 2017/2358 supplementing Directive (EU) 2016/97, Article 4, Product approval process. Official Journal L 341, 20 December 2017; EIOPA rulebook. Source
European Commission. (2017). Commission Delegated Regulation (EU) 2017/2358, Article 5, Target market. Official Journal L 341, 20 December 2017; EIOPA rulebook. Source
European Commission. (2017). Commission Delegated Regulation (EU) 2017/2358, Article 6, Product testing. Official Journal L 341, 20 December 2017; EIOPA rulebook. Source
European Commission. (2017). Commission Delegated Regulation (EU) 2017/2358, Article 7, Product monitoring and review. Official Journal L 341, 20 December 2017; EIOPA rulebook. Source
International Association of Insurance Supervisors (IAIS). (2024). Insurance Core Principles and Common Framework for the Supervision of Internationally Active Insurance Groups, December 2024. ICP 19, Conduct of Business, pp. 302-309. Source
Financial Conduct Authority (FCA). (2026). FCA Handbook, PROD 4.2, Manufacture of insurance products. Online rulebook, provisions and effective dates displayed in retrieved version. Source
National Association of Insurance Commissioners (NAIC). (n.d.). Annuity Suitability and Best Interest Standard. Insurance Topics; account of February 2020 Model 275 revisions. Source
European Insurance and Occupational Pensions Authority (EIOPA). (2026, June 30). EIOPA peer review follow-up shows progress in product oversight and governance supervision. Official news article. Source
Financial Conduct Authority (FCA). (2024a, February 9). GAP insurers agree to suspend sales following FCA concerns over fair value. Press release. Source
Financial Conduct Authority (FCA). (2024b, May 24). Firms to recommence GAP insurance sales following FCA action. Press release. Source
Financial Conduct Authority (FCA). (2024c, August 21). TR24/2: General insurance and pure protection product governance thematic review. Official findings summary. Source
Financial Conduct Authority (FCA). (2026). General insurance value measures data 2025. Official data publication. Source
Fama, E. F., & Jensen, M. C. (1983). Separation of Ownership and Control. Journal of Law and Economics, 26(2), 301-325. DOI: 10.1086/467037. Source
Lu, L., Yuan, Y. C., & McLeod, P. L. (2012). Twenty-Five Years of Hidden Profiles in Group Decision Making: A Meta-Analysis. Personality and Social Psychology Review, 16(1), 54-75. DOI: 10.1177/1088868311417243. Source